top of page
Eumedica AG FINAL.png

Ensuring Medical Care Continuity

Temgesic Visual V3.jpg

We are proud to announce that we recently completed the acquisition of TEMGESIC® / BUPREX® / BUPREXX® (Buprenorphine – Sublingual Tablets & Injections) rights outside North America from Indivior UK Ltd.  

With this acquisition, we demonstrate our willingness to keep on extending our activities by entering into a new therapeutic domain: the moderate to severe pain management. 

The strong brand equity of TEMGESIC® / BUPREX® / BUPREXX®, its key positioning and its particular features is enabling us to reinforce our purpose to guarantee that essential medicines remain accessible to the patients and to the healthcare professionals.


TEMGESIC® / BUPREX® / BUPREXX® is marketed in complementary countries to our current country scope and Eumedica will ensure the continuity of supply in these territories:

Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Luxembourg, The Netherlands, Spain, Sweden;

Australia, Hong Kong, Malaysia, New Zealand, Singapore, Taiwan;

As well as in United Kingdom, Norway, Switzerland & South Africa. 


We are looking to the future with enthusiasm, comforted by the quality of our team, of our approach and of our diversified portfolio of therapeutic solutions.

As a pharmaceutical company, Eumedica AG ensures the continuity of access to quality & lifesaving therapeutic solutions for healthcare practitioners and patients.


We focus on developing and maintaining a diversified range of therapeutic solutions that cover critical unmet medical needs.

Eumedica AG continuously develops its product portfolio of original drugs, actively used in hospitals as well as in retail channels.

Our product portfolio is made available worldwide thanks to a broad network of distributors and licensors.

bottom of page